{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:58:18Z","timestamp":1774522698831,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"DOI":"10.1186\/s12874-026-02799-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:16:00Z","timestamp":1771481760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping eligibility criteria in oncology target trial emulations using real-world data: a scoping review"],"prefix":"10.1186","volume":"26","author":[{"given":"Rou-Zhen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweta","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selen","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Wallach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi B.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"13","key":"2799_CR1","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials. BJOG. 2018;125(13):1716. https:\/\/doi.org\/10.1111\/1471-0528.15199.","journal-title":"BJOG"},{"issue":"2","key":"2799_CR2","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/curroncol30020143","volume":"30","author":"M Tang","year":"2023","unstructured":"Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing real-world evidence to advance cancer research. Curr Oncol. 2023;30(2):1844\u201359. https:\/\/doi.org\/10.3390\/curroncol30020143.","journal-title":"Curr Oncol"},{"issue":"1","key":"2799_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","volume":"20","author":"A Chari","year":"2020","unstructured":"Chari A, Romanus D, Palumbo A, et al. Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):8-17.e16. https:\/\/doi.org\/10.1016\/j.clml.2019.09.625.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2799_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1177\/17407745231193137","volume":"20","author":"JD Wallach","year":"2023","unstructured":"Wallach JD, Deng Y, Polley EC, et al. Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials. Clin Trials. 2023;20(6):689\u201398. https:\/\/doi.org\/10.1177\/17407745231193137.","journal-title":"Clin Trials"},{"issue":"24","key":"2799_CR5","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: a framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137. https:\/\/doi.org\/10.1001\/jama.2022.21383.","journal-title":"JAMA"},{"key":"2799_CR6","doi-asserted-by":"publisher","first-page":"e2400039","DOI":"10.1200\/cci.24.00039","volume":"8","author":"ML Berger","year":"2024","unstructured":"Berger ML, Ganz PA, Zou KH, Greenfield S. When will real-world data fulfill its promise to provide timely insights in oncology? JCO Clin Cancer Inform. 2024;8:e2400039. https:\/\/doi.org\/10.1200\/cci.24.00039.","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"2799_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/aje\/kwac202","volume":"192","author":"D Tompsett","year":"2023","unstructured":"Tompsett D, Zylbersztejn A, Hardelid P, De Stavola B. Target trial emulation and bias through missing eligibility data: an application to a study of palivizumab for the prevention of hospitalization due to infant respiratory illness. Am J Epidemiol. 2023;192(4):600\u201311. https:\/\/doi.org\/10.1093\/aje\/kwac202.","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2799_CR8","doi-asserted-by":"publisher","first-page":"e2336023","DOI":"10.1001\/jamanetworkopen.2023.36023","volume":"6","author":"HJ Hansford","year":"2023","unstructured":"Hansford HJ, Cashin AG, Jones MD, et al. Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review. JAMA Netw Open. 2023;6(9):e2336023. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36023.","journal-title":"JAMA Netw Open"},{"key":"2799_CR9","doi-asserted-by":"publisher","first-page":"e2200140","DOI":"10.1200\/cci.22.00140","volume":"7","author":"SA Kwee","year":"2023","unstructured":"Kwee SA, Wong LL, Ludema C, et al. Target trial emulation: a design tool for cancer clinical trials. JCO Clin Cancer Inform. 2023;7:e2200140. https:\/\/doi.org\/10.1200\/cci.22.00140.","journal-title":"JCO Clin Cancer Inform"},{"key":"2799_CR10","first-page":"616","volume":"2022","author":"J Kim","year":"2022","unstructured":"Kim J, Izower M, Quintana Y. Parsable clinical trial eligibility criteria representation using natural language processing. AMIA Annu Symp Proc. 2022;2022:616\u201324.","journal-title":"AMIA Annu Symp Proc"},{"key":"2799_CR11","first-page":"243","volume":"2020","author":"A Bompelli","year":"2020","unstructured":"Bompelli A, Li J, Xu Y, et al. Deep learning approach to parse eligibility criteria in dietary supplements clinical trials following OMOP common data model. AMIA Annu Symp Proc. 2020;2020:243\u201352.","journal-title":"AMIA Annu Symp Proc"},{"key":"2799_CR12","first-page":"950","volume":"245","author":"Y Si","year":"2017","unstructured":"Si Y, Weng C. An OMOP CDM-based relational database of clinical research eligibility criteria. Stud Health Technol Inform. 2017;245:950\u20134.","journal-title":"Stud Health Technol Inform"},{"key":"2799_CR13","doi-asserted-by":"publisher","first-page":"104649","DOI":"10.1016\/j.jbi.2024.104649","volume":"154","author":"J Park","year":"2024","unstructured":"Park J, Fang Y, Ta C, et al. Criteria2Query 3.0: leveraging generative large language models for clinical trial eligibility query generation. J Biomed Inform. 2024;154:104649. https:\/\/doi.org\/10.1016\/j.jbi.2024.104649.","journal-title":"J Biomed Inform"},{"issue":"6","key":"2799_CR14","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/aje\/kwae346","volume":"194","author":"JR Rider","year":"2025","unstructured":"Rider JR, Wasserman A, Slipski L, et al. Emulations of oncology trials using real-world data: a systematic literature review. Am J Epidemiol. 2025;194(6):1783\u201393. https:\/\/doi.org\/10.1093\/aje\/kwae346.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"2799_CR15","doi-asserted-by":"publisher","first-page":"e086595","DOI":"10.1136\/bmjopen-2024-086595","volume":"14","author":"N Simon-Tillaux","year":"2024","unstructured":"Simon-Tillaux N, Martin GL, Hajage D, et al. Conducting observational analyses with the target trial emulation approach: a methodological systematic review. BMJ Open. 2024;14(11):e086595. https:\/\/doi.org\/10.1136\/bmjopen-2024-086595.","journal-title":"BMJ Open"},{"issue":"2","key":"2799_CR16","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/pharma2020013","volume":"2","author":"TW Wilson","year":"2023","unstructured":"Wilson TW, Dye JT, Spark S, Robert NJ, Espirito JL, Amirian ES. Feasibility of using oncology-specific electronic health record (EHR) data to emulate clinical trial eligibility criteria. Pharmacoepidemiology. 2023;2(2):140\u20137.","journal-title":"Pharmacoepidemiology"},{"issue":"1","key":"2799_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12874-024-02307-1","volume":"24","author":"GS Janda","year":"2024","unstructured":"Janda GS, Jeffery MM, Ramachandran R, Ross JS, Wallach JD. Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study. BMC Med Res Methodol. 2024;24(1):187. https:\/\/doi.org\/10.1186\/s12874-024-02307-1.","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"2799_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaoncol.2022.1664","volume":"8","author":"DE Gerber","year":"2022","unstructured":"Gerber DE, Singh H, Larkins E, et al. A new approach to simplifying and harmonizing cancer clinical trials-standardizing eligibility criteria. JAMA Oncol. 2022;8(9):1333\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1664.","journal-title":"JAMA Oncol"},{"issue":"10","key":"2799_CR19","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/jbies-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119\u201326. https:\/\/doi.org\/10.11124\/jbies-20-00167.","journal-title":"JBI Evid Synth"},{"issue":"7","key":"2799_CR20","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/m18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/m18-0850.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2799_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"key":"2799_CR22","unstructured":"(OHDSI) OHDSaI. Standardized data: the OMOP common data model. https:\/\/www.ohdsi.org\/data-standardization\/. Accessed 29 Sep 2025."},{"issue":"7","key":"2799_CR23","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnci\/djae024","volume":"116","author":"J Kirkeg\u00e5rd","year":"2024","unstructured":"Kirkeg\u00e5rd J, Gaber C, Heide-J\u00f8rgensen U, et al. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. J Natl Cancer Inst. 2024;116(7):1072\u20139. https:\/\/doi.org\/10.1093\/jnci\/djae024.","journal-title":"J Natl Cancer Inst"},{"key":"2799_CR24","doi-asserted-by":"publisher","unstructured":"Kirkeg\u00e5rd J, Ladekarl M, Johannsen IR, Mortensen F. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation. Br J Surg. 2024;111(1). https:\/\/doi.org\/10.1093\/bjs\/znad398.","DOI":"10.1093\/bjs\/znad398"},{"issue":"2","key":"2799_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1245\/s10434-023-14497-x","volume":"31","author":"J Kirkeg\u00e5rd","year":"2024","unstructured":"Kirkeg\u00e5rd J, Ladekarl M, Lund A, Mortensen F. Impact on survival of early versus late initiation of adjuvant chemotherapy after pancreatic adenocarcinoma surgery: a target trial emulation. Ann Surg Oncol. 2024;31(2):1310\u20138. https:\/\/doi.org\/10.1245\/s10434-023-14497-x.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2799_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1504627.","journal-title":"N Engl J Med"},{"issue":"2","key":"2799_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/aje\/kwae226","volume":"194","author":"S Schneeweiss","year":"2025","unstructured":"Schneeweiss S, Desai RJ, Ball R. A future of data-rich pharmacoepidemiology studies: transitioning to large-scale linked electronic health record\u00a0+\u00a0claims data. Am J Epidemiol. 2025;194(2):315\u201321. https:\/\/doi.org\/10.1093\/aje\/kwae226.","journal-title":"Am J Epidemiol"},{"issue":"10","key":"2799_CR28","doi-asserted-by":"publisher","first-page":"e70028","DOI":"10.1002\/pds.70028","volume":"33","author":"RJ Desai","year":"2024","unstructured":"Desai RJ, Marsolo K, Smith J, et al. The FDA sentinel Real World Evidence Data Enterprise (RWE-DE). Pharmacoepidemiol Drug Saf. 2024;33(10):e70028.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2799_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3587","volume":"4","author":"DJ Boyne","year":"2021","unstructured":"Boyne DJ, Cheung WY, Hilsden RJ, et al. Association of a shortened duration of adjuvant chemotherapy with overall survival among individuals with stage III colon cancer. JAMA Netw Open. 2021;4(3):e213587-e213587. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3587.","journal-title":"JAMA Netw Open"},{"issue":"7855","key":"2799_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","volume":"592","author":"R Liu","year":"2021","unstructured":"Liu R, Rizzo S, Whipple S, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021;592(7855):629\u201333. https:\/\/doi.org\/10.1038\/s41586-021-03430-5.","journal-title":"Nature"},{"issue":"9","key":"2799_CR31","doi-asserted-by":"publisher","first-page":"e2436535","DOI":"10.1001\/jamanetworkopen.2024.36535","volume":"7","author":"D Merola","year":"2024","unstructured":"Merola D, Campbell U, Lenis D, et al. Calibrating observational health record data against a randomized trial. JAMA Netw Open. 2024;7(9):e2436535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.36535.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2799_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41591-024-03352-5","volume":"31","author":"X Orcutt","year":"2025","unstructured":"Orcutt X, Chen K, Mamtani R, Long Q, Parikh RB. Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations. Nat Med. 2025;31(2):457\u201365. https:\/\/doi.org\/10.1038\/s41591-024-03352-5.","journal-title":"Nat Med"},{"issue":"16","key":"2799_CR33","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","volume":"329","author":"SV Wang","year":"2023","unstructured":"Wang SV, Schneeweiss S. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023;329(16):1376\u201385. https:\/\/doi.org\/10.1001\/jama.2023.4221.","journal-title":"JAMA"},{"issue":"2","key":"2799_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40801-023-00353-7","volume":"10","author":"R Wakabayashi","year":"2023","unstructured":"Wakabayashi R, Hirano T, Koga T, Kuwatsuru R. An attempt to replicate randomized trials of diabetes treatments using a Japanese administrative claims and health checkup database: a feasibility study. Drugs Real World Outcomes. 2023;10(2):235\u201347. https:\/\/doi.org\/10.1007\/s40801-023-00353-7.","journal-title":"Drugs Real World Outcomes"},{"key":"2799_CR35","doi-asserted-by":"publisher","unstructured":"Benz L, Mukherjee R, Wang R, et al. Adjusting for selection bias due to missing eligibility criteria in emulated target trials. Am J Epidemiol. 2024:kwae471. https:\/\/doi.org\/10.1093\/aje\/kwae471.","DOI":"10.1093\/aje\/kwae471"},{"issue":"11","key":"2799_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jamainternmed.2023.4073","volume":"183","author":"GS Janda","year":"2023","unstructured":"Janda GS, Wallach JD, Dhodapkar MM, Ramachandran R, Ross JS. Feasibility of emulating clinical trials supporting US FDA supplemental indication approvals of drugs and biologics. JAMA Intern Med. 2023;183(11):1271\u20133. https:\/\/doi.org\/10.1001\/jamainternmed.2023.4073.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"2799_CR37","doi-asserted-by":"publisher","first-page":"AIoa2400859","DOI":"10.1056\/AIoa2400859","volume":"2","author":"J Gonz\u00e1lez","year":"2025","unstructured":"Gonz\u00e1lez J, Ueno R, Wong C, et al. TRIALSCOPE\u2014a framework for clinical trial simulation from real-world data. NEJM AI. 2025;2(10):AIoa2400859.","journal-title":"NEJM AI"},{"key":"2799_CR38","doi-asserted-by":"publisher","unstructured":"Guan Z, Zeng D, Li H, Wong TY, Sheng B. Can generative artificial intelligence empower target trial emulations? Lancet Digit Health. https:\/\/doi.org\/10.1016\/j.landig.2025.100950.","DOI":"10.1016\/j.landig.2025.100950"},{"issue":"4","key":"2799_CR39","doi-asserted-by":"publisher","first-page":"102081","DOI":"10.1016\/j.xcrm.2025.102081","volume":"6","author":"X Liang","year":"2025","unstructured":"Liang X, Zhang D, Wang H, et al. Importance of cohort and target trial emulation in clinical research. Cell Rep Med. 2025;6(4):102081. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102081.","journal-title":"Cell Rep Med"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-026-02799-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-026-02799-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-026-02799-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:57:38Z","timestamp":1774519058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12874-026-02799-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1186\/s12874-026-02799-z","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this scoping review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.D.W. is supported by Arnold Ventures, the US Food and Drug Administration through the Yale-Mayo CERSI, Johnson & Johnson through the Yale Open Data Access project, and the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under awards 1K01AA028258 and 1R01AA032254 and previously served as a consultant to Hagens Berman Sobol Shapiro LLP and Dugan Law Firm APLC. R.B.P. discloses grants from the National Institutes of Health, Department of Defense, Prostate Cancer Foundation, NCCN Foundation, Humana, Emerson Collective, Schmidt Futures, Arnold Ventures, Mendel.ai, and Veterans Health Administration; personal fees and equity from GNS Healthcare, Thyme Care, Main Street Health, Optinosis, and Onc.AI; personal fees from ConcertAI, Cancer Study Group, Mendel.ai, Biofourmis, Archetype Therapeutics, CreditSuisse, G1 Therapeutics, Humana, and Nanology; stock options in Counsel Health; honoraria from Flatiron and Medscape; has board membership (unpaid) at the Coalition to Transform Advanced Care and American Cancer Society; editorship at the Journal of Clinical Oncology; and serving on a leadership consortium (unpaid) at the National Quality Forum, all outside the submitted work. All other authors have no competing interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}